News

Vienna, Austria—December 7, 2016—Today’s press briefing at the IASLC 17th World Conference on Lung Cancer (WCLC) focused on clinical trials that advance the progress made in lung cancer treatment through immunotherapy and better diagnostics. Abstracts and full versions of news releases for each topic covered are available through links in this summary, or through IASLC media representative Chris Martin at cmartin@davidjamesgroup.com.

Vienna, Austria—December 6, 2016—Today’s press briefing at the IASLC 17th World Conference on LungCancer(WCLC) focused on active prevention, with researchers sharing results of clinical drug trials that have shown reduction in risk of disease progression among lung cancer patients.

Vienna, Austria—December 5, 2016—Efforts to control tobacco as a public health threat have escalated as clinicians and public health advocates have coalesced to beat back threats from tobacco companies through public advocacy, public health, and pension reform.

Vienna, Austria—December 4, 2016—Global lung cancer researchers and patient advocates today emphasized that new models of delivering care and communicating about cancer care play an important role in the fight against lung cancer. Their remarks come on the first day of the IASLC 17th World Conference onLung Cancer (WCLC) in Vienna, Austria.

Today the JTO, the official journal of the IASLC, published “PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the “Blueprint PD-L1 IHC Assay Comparison Project”. The IASLC has taken a leadership role in this important industrial-academic partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC assays

DENVER – The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.

Pages